AnPac Bio-Medical Science Co., Ltd. (Form: 6-K, Received: 02/15/2022 16:31:05)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2022

Commission File Number: 001-39137

ANPAC BIO-MEDICAL SCIENCE CO., LTD.

(Translation of registrant’s name into English)

801 Bixing Street, Bihu County

Lishui, Zhejiang Province 323006

The People’s Republic of China

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On May 31, 2021, AnPac Bio-Medical Science Co., Ltd. (the “Company”) entered into a debt settlement and mutual release agreement with Ascent Investor Relations Inc (“Ascent”), the Company’s investors relations consultant. As of the date of the debt settlement and mutual release agreement, the Company was indebted to Ascent for accrued but unpaid service fee in the amount of US$703,080. In order to settle such indebtedness, the Company issued a convertible debenture in the principal amount of US$703,080 (the “Ascent Convertible Debenture”) pursuant to the debt settlement and mutual release agreement.

The Ascent Convertible Debentures will mature twelve months after issuance and carries an interest rate of 0% per year, subject to certain condition that may increase the rate to 15% per year. The Ascent Convertible Debentures can be converted into our American depositary shares (“ADSs”), each representing one Class A ordinary share, par value US$0.01 per share, at any time on or prior to maturity at the lower of (i) US$15.00, or (ii) the lower of (x) 82% of the closing bid price in the last reported trade of the ADSs or (y) 80% of the VWAPs (daily dollar volume-weighted average price) during the 10 consecutive trading days, immediately preceding the date of conversion or other date of determination (the “Variable Conversion Price”), but not lower than the floor price.

On February 5, 2022, the Company entered into an amendment agreement with Ascent, pursuant to which the floor price of the Ascent Convertible Debenture was reduced to US$0.10 per share.

The foregoing description of the debt settlement and mutual release agreement and the amendment agreement with Ascent are qualified in their entirety by reference to the full text thereof, which are attached as Exhibits 10.1 and 10.2 hereto and incorporated by reference herein.

As previously disclosed on the report of foreign private issuer on Form 6-K on July 22, 2021, on July 20, 2021, the Company entered into a securities purchase Agreement with certain investors pursuant to which the Company issued convertible debentures (the “Registered Convertible Debentures”) in a registered direct offering in the principal amount of US$3,014,000 at the aggregate price of US$2,740,000 on July 22, 2021. As of the date of this report, there is a total principal amount of US$2,490,814.89 outstanding under the Registered Convertible Debentures.

On February 5, 2022, the Company entered into an amendment agreement with the holders of the Registered Convertible Debentures, pursuant to which the floor price of the Registered Convertible Debentures was reduced to US$0.10 per share.

The foregoing description of the amendment agreement with the holders of the Registered Convertible Debentures is qualified in its entirety by reference to the full text thereof, a form of which is attached as Exhibits 10.3 hereto and incorporated by reference herein.

EXHIBIT INDEX

Exhibit No.		Description
10.1		Debt Settlement and Mutual Release Agreement between the Company and Ascent Investor Relations Inc, dated May 31, 2021
10.2		Amendment Agreement between the Company and Ascent Investor Relations Inc, dated February 5, 2022
10.3		Form of Amendment Agreement between the Company and certain convertible debenture holders, dated February 5, 2022

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: February 15, 2022	ANPAC BIO-MEDICAL SCIENCE CO., LTD.

	By:	/s/ Chris Chang Yu
	Name:	Chris Chang Yu
	Title:	Chief Executive Officer and Chairman of the Board

Exhibit 10.1

Debt Settlement and Mutual Release Agreement

Dated as of May 31, 2021

This Debt Settlement and Mutual Release Agreement (the “Agreement”) is entered into as of the date first set forth above (the “Effective Date”), by and between (i) AnPac Bio-Medical Science Co., Ltd., a British Virgin Islands company (the “Company”) and (ii) Ascent Investor Relations Inc. (“Ascent”). Each of the Company and Ascent may be referred to herein individually as a “Party” and collectively as the “Parties.”

WHEREAS, the Company entered into an engagement agreement (the “Engagement Agreement”) with Ascent on November 26, 2019, pursuant to which the company agreed to pay Ascent a fee of $15,000 per month before the Company’s listing on Nasdaq and either $12,500 per month after listing on Nasdaq if the total amount raised by the Company in its initial public offering is greater than $12.5 million, or $7,500 per month if the total amount raised by the Company in its initial public offering is less than $12.5 million, for a term from November 26, 2019 to November 25, 2020, in exchange for Ascent’s investor relations services.

WHEREAS, the Company entered into a supplementary provisions to the service agreement on January 1, 2020 (the “Supplementary Agreement”) with Ascent on January 1, 2020, pursuant to which the company agreed to pay Ascent a total of $1,500,000, for a term from January 1, 2020 to December 31, 2021, in exchange for Ascent’s additional investor relations services.

WHEREAS, the services covered by the Supplementary Agreement are beyond the scope of the services in the Engagement Agreement. The fee shall be paid separately.

WHEREAS, as of the Effective Date, Ascent has an outstanding invoice in the amount of $103,080 pursuant to the Engagement Agreement and an outstanding invoice in the amount of $600,000 pursuant to the Supplementary Agreement (collectively, the “Debt”).

WHEREAS, the Parties now wish to settle the Debt subject to the terms and conditions as set forth herein; and

NOW, THEREFORE, in consideration of the premises and of the terms and conditions herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows:

Cancellation and Release of Debt. Effective as of the Effective Date, the Parties acknowledge and agree that the Debt is hereby cancelled in all respects and shall be of no further force or effect and, to the extent payable, shall be deemed paid in full. Ascent represents and warrants that the Debt represents the total amount due or possibly due to Ascent by the Company and there are no other loans or amounts due to Ascent by the Company.

Issuance of Convertible Debenture. Effective as of the Effective Date, the Company agrees to issue a convertible debenture in the principal amount of $703,080 (the “Convertible Debenture”) in the form as attached herein as Exhibit A to Ascent. The Convertible Debenture will mature in twelve months on May 30, 2022 and carries an interest rate of 0% per year, subject to certain condition that may increase the rate to 15% per year. Ascent may convert the Convertible Debenture into the Company’s ADSs, each currently representing one Class A ordinary share of the Company, at any time on or prior to maturity. The Convertible Debenture was issued in reliance upon an exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). The Convertible Debenture, the ADSs issuable upon conversion of the Convertible Debenture and the Class A ordinary shares that may be issued if ADS are exchanged for the underlying Class A ordinary shares shall be endorsed with the following restrictive legends:

“[NEITHER] THIS [SECURITY] [NOR THE SECURITIES INTO WHICH THIS [SECURITY] IS [CONVERTIBLE/EXCHANGABLE] [HAS NOT/HAVE] BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.”

Release of Claims.

(a)

Effective as of the Effective Date, the Company and its successors, assigns, heirs, representatives, and agents and for all related parties, and all persons acting by, through, under or in concert with any of them in both their official and personal capacities (collectively, the “Company Parties”) hereby irrevocably, unconditionally and forever release, discharge and remise Ascent and its Affiliates (whether an Affiliate as of the Effective Date or later), and their respective predecessors, successors, assigns, heirs, representatives, and agents and for all related parties and all persons acting by, through, under or in concert with any of them in both their official and personal capacities (collectively, the “Ascent Parties”), from all claims of any type and all manner of action and actions, cause and causes of action, suits, debts, dues, sums of money, accounts, reckonings, bonds, bills, specialties, covenants, contracts, controversies, agreements, promises, variances, trespasses, damages, judgments, executions, claims and demands whatsoever, in law or in equity, known or unknown, that any Company Party may have now or may have in the future, against any of the Ascent Parties to the extent that those claims arose, may have arisen, or are based on events which occurred at any point in the past up to and including the Effective Date, other than any claims arising pursuant to this Agreement (collectively, the “Company Released Claims”). The Company represents and warrants that no Company Released Claim released herein has been assigned, expressly, impliedly, or by operation of law, and that all Company Released Claims released herein are owned by the Company, which has the respective sole authority to release them. The Company agrees that it shall forever refrain and forebear from commencing, instituting or prosecuting any lawsuit action or proceeding, judicial, administrative or otherwise collect or enforce any Company Released Claim which is released and discharged herein. For purposes hereof, an “Affiliate” of a Party shall be any Party that controls, is controlled by, or is under common control with, the subject Party.

(b)

Effective as of the Effective Date, Ascent, for himself and the other Ascent Parties, hereby irrevocably, unconditionally and forever releases, discharges and remises each Company Party, from all claims of any type and all manner of action and actions, cause and causes of action, suits, debts, dues, sums of money, accounts, reckonings, bonds, bills, specialties, covenants, contracts, controversies, agreements, promises, variances, trespasses, damages, judgments, executions, claims and demands whatsoever, in law or in equity, known or unknown, that any Ascent Party may have now or may have in the future, against any of the Company Parties to the extent that those claims arose, may have arisen, or are based on events which occurred at any point in the past up to and including the Effective Date, other than any claims arising pursuant to this Agreement (collectively, the “Ascent Released Claims”). Ascent represents and warrants that no Ascent Released Claim released herein has been assigned, expressly, impliedly, or by operation of law, and that all Ascent Released Claims released herein are owned by Ascent, who has the sole authority to release them. Ascent agrees that he shall forever refrain and forebear from commencing, instituting or prosecuting any lawsuit action or proceeding, judicial, administrative or otherwise collect or enforce any Ascent Released Claim which is released and discharged herein.

Covenant Not to File a Claim and Indemnification.

(a)

Each of the Company Parties agrees not to file for themselves or on behalf of any other parties, any claim, charge, complaint, action, or cause of action against any Ascent Party related to the Company Released Claims, and further agrees to indemnify and save harmless such Ascent Parties from and against any and all losses, including, without limitation, the cost of defense and legal fees, occurring as a result of any claims, charges, complaints, actions, or causes of action made or brought by any such Company Party against any Ascent Party in violation of the terms and conditions of this Agreement. In the event that any Company Party brings a suit against any Ascent Party in violation of this covenant, the Company agrees to pay any and all costs of the Ascent Parties, including attorneys’ fees, incurred by such Ascent Parties in challenging such action. Any Ascent Party is an intended third-party beneficiary of this Agreement.

(b)

Each of the Ascent Parties agrees not to file for themselves or on behalf of any other parties, any claim, charge, complaint, action, or cause of action against any Company Party related to the Ascent Released Claims, and further agrees to indemnify and save harmless such Company Parties from and against any and all losses, including, without limitation, the cost of defense and legal fees, occurring as a result of any claims, charges, complaints, actions, or causes of action made or brought by any such Ascent Party against any Company Party in violation of the terms and conditions of this Agreement. In the event that any Ascent Party brings a suit against any Company Party in violation of this covenant, Ascent agrees to pay any and all costs of the Company Parties, including attorneys’ fees, incurred by such Company Parties in challenging such action. Any Company Party is an intended third-party beneficiary of this Agreement.

Affirmations.

(a)

Each Company Party affirms that it has not filed, caused to be filed, or presently is a party to any claim, complaint, or action against any Ascent Party in any forum or form and should any such charge or action be filed by any Company Party or by any other person or entity on any Company Party’s behalf involving matters covered by Section 3(a), the Company agrees to promptly give the agency or court having jurisdiction a copy of this Agreement and inform them that any such claims any such Company Party might otherwise have had are now settled.

(b)

Each Ascent Party affirms that it has not filed, caused to be filed, or presently is a party to any claim, complaint, or action against any Company Party in any forum or form and should any such charge or action be filed by any Ascent Party or by any other person or entity on any Ascent Party’s behalf involving matters covered by Section 3(b), Ascent agrees to promptly give the agency or court having jurisdiction a copy of this Agreement and inform them that any such claims any such Ascent Party might otherwise have had are now settled.

(c)

This is a compromise and settlement of potential or actual disputed claims and is made solely for the purpose of avoiding the uncertainty, expense, and inconvenience of future litigation. Neither this Agreement nor the furnishing of any consideration concurrently with the execution hereof shall be deemed or construed at any time or for any purpose as an admission by any Party of any liability or obligation of any kind. Any such liability or wrongdoing is expressly denied. The Parties hereto acknowledge that this Agreement was reached after good faith settlement negotiations and after each party had an opportunity to consult legal counsel. This Agreement extends to, and is for the benefit of, the Parties, their respective successors, assigns and agents and anyone claiming by, through or under the Parties hereto.

Additional Agreements. This Agreement shall be effective upon its execution by each of the Parties hereto. Each of the Parties hereto shall execute such documents and perform such further acts as may be reasonably required to carry out the provisions hereof and the actions contemplated hereby. No Party shall, and each Party shall cause their respective Affiliates not to, in each case, whether directly or indirectly, for itself or through or on behalf of any other Party not to, make any disparaging comments (or induce or encourage others to make disparaging comments) about any other Party or its officers, directors, shareholders, employees and agents, or their respective operations, financial condition, prospects, products or services.

Representations and Warranties.

(a)

Ascent represents and warrants to the Company as follows:

(i)

Ascent has all requisite authority and power to execute and deliver this Agreement and the other documents referenced herein to which he is or will be a party and to perform his obligations hereunder and thereunder. The execution and delivery of this Agreement, as well as the consummation of the transactions contemplated hereby, has been duly and validly authorized by all necessary action on the part of Ascent and no other action or proceedings on the part of Ascent are or will be necessary to authorize the execution, delivery and performance of this Agreement or the transactions contemplated hereby on the part of Ascent.

(ii)

This Agreement has been duly executed and delivered by Ascent and, assuming that this Agreement constitutes the legal, valid and binding obligation of the Company, constitutes the legal, valid, and binding obligation of Ascent, enforceable against Ascent in accordance with its terms except to the extent that the enforceability thereof may be limited by (a) applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and other similar laws of general application affecting enforcement of creditors’ rights generally and (b) general principles of equity (the “Enforceability Exceptions”).

(iii)

Neither the execution and delivery of this Agreement nor the consummation and performance of any of the transactions contemplated hereby by Ascent will violate in any material respect any existing applicable law, rule, regulation, judgment, order or decree of any governmental authority having jurisdiction over Ascent, provided, however, that no representation or warranty is made in this subsection with respect to matters that would not, individually or in the aggregate, reasonably be expected to materially delay or materially impair Ascent’s ability to consummate transactions contemplated hereby.

(b)

The Company represents and warrants to Ascent as follows:

(i)

The Company has all requisite corporate authority and power to execute and deliver this Agreement and the other documents referenced herein to which either of them are or will be a party and to perform their respective obligations hereunder and thereunder. No other action or proceedings on the part of the Company are or will be necessary to authorize the execution, delivery and performance of this Agreement or the transactions contemplated hereby on the part of the Company.

(ii)

This Agreement has been duly executed and delivered by the Company and, assuming that this Agreement constitutes the legal, valid and binding obligation of Ascent, constitutes the legal, valid, and binding obligation of the Company, enforceable against the Company in accordance with its terms except to the extent that the enforceability thereof may be limited by the Enforceability Exceptions.

(iii)

Neither the execution and delivery of this Agreement nor the consummation and performance of any of the transactions contemplated hereby or thereby by the Company will violate in any material respect any existing applicable law, rule, regulation, judgment, order or decree of any governmental authority having jurisdiction over the Company; provided, however, that no representation or warranty is made in this subsection with respect to matters that would not, individually or in the aggregate, reasonably be expected to materially delay or materially impair the Company’s ability to consummate transactions contemplated hereby.

Notices. All notices, requests, consents, claims, demands, waivers and other communications hereunder (each, a “Notice”) shall be in writing. All Notices shall be delivered by personal delivery, nationally recognized overnight courier (with all fees pre-paid), e-mail of a PDF document (with confirmation of transmission) or certified or registered mail (in each case, return receipt requested, postage prepaid). Except as otherwise provided in this Agreement, a Notice is effective only (a) upon receipt by the receiving party, and (b) if the party giving the Notice has complied with the requirements of this Section.

Governing Law and Interpretation. This Agreement shall be governed and controlled by and in accordance with the laws of the State of New York without regard to its conflict of laws provisions. Venue for any action brought to enforce the terms of this Agreement or for breach thereof shall lie exclusively in the state and federal courts located in New York County, New York. Should any provision of this Agreement be declared illegal or unenforceable by any court of competent jurisdiction and cannot be modified to be enforceable, excluding the general release language, such provision shall immediately become null and void, leaving the remainder of this Agreement in full force and effect. The Parties affirm that this Agreement is the product of negotiation and agree that it shall not be construed against any Party on the basis of sole authorship. The Parties agree that the successful Party in any suit related to this Agreement (as determined by the applicable court(s)) shall be entitled to recover its reasonable attorneys’ fees and expenses related thereto, including attorneys’ fees and costs incident to an appeal.

10.

Waiver of Jury Trial. Each party hereto waives, to the fullest extent permitted by applicable law, any right he or it may have to a trial by jury in any legal proceeding directly or indirectly arising out of or relating to this agreement or the transactions contemplated herein or the performance thereof (whether based on contract, tort or any other theory). Each party hereto (A) certifies that no representative, agent or attorney of any other party has represented, expressly or otherwise, that such other party would not, in the event of litigation, seek to enforce the foregoing waiver and (B) acknowledges that it and the other party hereto has been induced to enter into this agreement by, among other things, the mutual waivers and certifications in this section.

11.

Remedies. Each of the Parties acknowledges and agrees that the remedy at law available to the other Party for breach of any Party’s obligations under this Agreement would be inadequate and that damages flowing from such a breach may not readily be susceptible to being measured in monetary terms. Accordingly, each Party acknowledges, consents and agrees that, in addition to any other rights or remedies that any Party may have at law, in equity or under this Agreement, upon adequate proof of a violation by any other Party of any provision of this Agreement, the first Party will be entitled to seek immediate injunctive relief and may obtain a temporary order restraining any threatened or further breach, without the necessity of proof of actual damage or requirement to post a bond.

12.

Non-admission of Wrongdoing. The Parties agree neither this Agreement nor the furnishing of the consideration for same shall be deemed or construed at any time for any purpose as an admission by any Party of any liability or unlawful conduct of any kind.

13.

Entire Agreement; Severability. This Agreement and the exhibits attached hereto sets forth the entire agreement between the Parties with respect to the subject matter hereof and fully supersedes any prior agreements or understandings between the Parties with respect to the subject matter hereof. The Parties acknowledge that each has not relied on any representations, promises, or agreements of any kind made to the other in connection with each Party’s decision to accept this Agreement, except for those set forth in this Agreement. If any provision of this Agreement is held to be illegal, invalid, or unenforceable under present or future laws effective during the term hereof, the provision shall be fully severable and this Agreement shall be construed and enforced as if such illegal, invalid, or unenforceable provision were never a part hereof; and the remaining provisions hereof shall remain in full force and effect and shall not be affected by the illegal, invalid, or unenforceable provision or by its severance herefrom. The Parties have participated in the drafting and negotiation of this Agreement and if an ambiguity or question of interpretation should arise, this Agreement shall be construed as if drafted jointly by the Parties thereto and no presumption of burden of proof shall arise favoring or burdening any Party by virtue of the authorship of any provision in this Agreement.

14.

Amendment. This Agreement may not be modified, altered or changed except upon express written consent of all Parties wherein specific reference is made to this Agreement.

15.

Headings. The headings contained in this Agreement are intended solely for convenience and shall not affect the rights of the Parties to this Agreement.

16.

Waiver. Waiver of any term or condition of this Agreement by any Party shall only be effective if in writing and shall not be construed as a waiver of any subsequent breach or failure of the same term or condition, or a waiver of any other term or condition of this Agreement.

17.

Binding Effect; Assignment. This Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their permitted successors and assigns. No Party to this Agreement may assign or delegate, by operation of law or otherwise, all or any portion of its rights, obligations or liabilities under this Agreement without the prior written consent of the other Party to this Agreement, which any such Party may withhold in its absolute discretion. Any purported assignment without such prior written consents shall be void.

18.

No Third-Party Beneficiaries. Other than as specifically set forth herein, nothing in this Agreement shall confer any rights, remedies or claims upon any person or entity not a Party or a permitted assignee of a Party to this Agreement.

19.

Expenses. Except as expressly provided herein, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the Party incurring such costs and expenses.

20.

Counterparts. This Agreement may be signed in any number of counterparts with the same effect as if the signatures to each counterpart were upon a single instrument, and all such counterparts together shall be deemed an original of this Agreement.

[Signatures appear on following page]

IN WITNESS WHEREOF, the Parties hereto knowingly and voluntarily executed this Agreement as of the Effective Date:

	AnPac Bio-Medical Science Co., Ltd.

	By:	/s/ Chris Change Yu
	Name:	Chris Chang Yu
	Title:	Chairman of the Board of Directors and Chief Executive Officer

	Ascent Investor Relations Inc.

	By:	/s/ Tina Xiao
	Name:	Tina Xiao
	Title:	President

Exhibit 10.2

AMENDMENT AGREEMENT

This Amendment Agreement (the “Agreement”), dated as of February 5, 2022, is entered into by and between Anpac Bio-Medical Science Co., Ltd., a British Virgin Islands exempted company (the “Company”), and Ascent Investor Relations Inc. (the “Holder”), and amends the convertible debenture in the principal amount of $703,080 issued by the Company to the Holder on May 31, 2021 (the “Convertible Debenture”) pursuant to a Securities Purchase Agreement entered into between the Company and the Holder on May 31, 2021 (the “Securities Purchase Agreement”).

BACKGROUND

(A)

The Convertible Debenture is convertible into ADSs of the Company pursuant to their terms subject to a floor price of $1.00 per share.

(B)

The parties desire to reduce the floor price with respect to the Convertible Debenture pursuant to the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the foregoing recitals and representations, warranties and covenants herein set forth, the parties hereto agree as follows:

Definitions and interpretation

1.1 Capitalized terms not otherwise defined herein shall have the meanings set forth in the Convertible Debenture.

Amendments to the Convertible Debentures

The parties hereto agree that the Convertible Debenture and shall be amended as set out below without the need to issue amended and restated certificates of such Convertible Debenture.

2.1 Amendment of Convertible Debenture. The definition of “Floor Price” in section 13(j) of the Convertible Debenture shall be deleted and replaced with the following:

13(j) “Floor Price” means $0.10 per share.

Representations and warranties

3.1

Each party to this Agreement represents and warrants to the other as of the date of this Agreement that:

(a) it has the requisite corporate power and authority to enter into this Agreement and to consummate the transactions contemplated by this Agreement;

(b) it has taken all necessary corporate actions to authorize the execution, delivery and performance of this Agreement and no further action is required by it, its Board of Directors or managers or its stockholders or members in connection therewith; and

(c) the obligations assumed by it in this Agreement are legal, valid, and enforceable obligations binding on it in accordance with its terms.

3.2 The Company represents and warrants to the Holder that any additional shares that may be issued as a result of this Agreement have been duly authorized and, when issued in accordance with the terms of the Convertible Debentures, shall be validly issued and duly authorized.

Counterparts and delivery

This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.

Governing law

This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under the Securities Purchase Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, the Company and the Holder have caused this Amendment Agreement to be signed by their duly authorized officers.

	ANPAC BIO-MEDICAL SCIENCE CO., LTD.

	By:	/s/ Chris Change Yu
	Name:	Chris Chang Yu
	Title:	Chairman of the Board of Directors and Chief Executive Officer

	ASCENT INVESTOR RELATIONS INC.

	By:	/s/ Tina Xiao
	Name:	Tina Xiao
	Title:	President

Exhibit 10.3

AMENDMENT AGREEMENT

This Amendment Agreement (the “Agreement”), dated as of February 5, 2022, is entered into by and between Anpac Bio-Medical Science Co., Ltd., a British Virgin Islands exempted company (the “Company”), and the parties named on the signature pages hereto (each a “Holder” and collectively, the “Holders”), and amends the convertible debentures in the aggregate principal amount of $3,014,000 issued by the Company to the Holder on July 20, 2021 (the “Convertible Debentures”) pursuant to a Securities Purchase Agreement entered into between the Company and the Holders on July 20, 2021 (the “Securities Purchase Agreement”).

BACKGROUND

(A)

The Convertible Debentures are convertible into ADSs of the Company pursuant to their terms subject to a floor price of $2.50 per share. If the Closing Bid Price during each of the 10 consecutive Trading Days immediately preceding the Conversion Date or other date of determination is lower than $2.50, the Floor Price shall be adjusted to equal the average Closing Bid Price of the 10 consecutive Trading Days immediately preceding the Conversion Date. But in no event should the Floor Price be lower than $1.00 per share.

(B)

The parties desire to reduce the floor price with respect to the Convertible Debentures pursuant to the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the foregoing recitals and representations, warranties and covenants herein set forth, the parties hereto agree as follows:

Definitions and interpretation

1.1 Capitalized terms not otherwise defined herein shall have the meanings set forth in the Convertible Debentures.

Amendments to the Convertible Debentures

The parties hereto agree that the Convertible Debentures and shall be amended as set out below without the need to issue amended and restated certificates of such Convertible Debentures.

2.1 Amendment of Convertible Debentures. The definition of “Floor Price” in section 13(j) of the Convertible Debentures shall be deleted and replaced with the following: